UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.84M | 27.48M | 24.22M | 20.25M | 24.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.84M | 27.48M | 24.22M | 20.25M | 24.57M |
| Cost of Revenue | 3.29M | 3.28M | 3.55M | 2.33M | 2.47M |
| Gross Profit | 34.55M | 24.20M | 20.67M | 17.92M | 22.09M |
| SG&A Expenses | 39.35M | 37.58M | 43.20M | 34.97M | 35.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.95M | 54.87M | 65.66M | 57.17M | 53.32M |
| Operating Income | -19.12M | -27.39M | -41.45M | -36.91M | -28.76M |
| Income Before Tax | -26.64M | -34.40M | -48.93M | -43.45M | -34.86M |
| Income Tax Expenses | -275.00K | -1.05M | 1.02M | 392.00K | 2.65M |
| Earnings from Continuing Operations | -26.36M | -33.35M | -49.94M | -43.84M | -37.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.36M | -33.35M | -49.94M | -43.84M | -37.51M |
| EBIT | -19.12M | -27.39M | -41.45M | -36.91M | -28.76M |
| EBITDA | -19.04M | -26.41M | -41.37M | -36.84M | -28.69M |
| EPS Basic | -0.54 | -0.69 | -1.05 | -0.92 | -0.80 |
| Normalized Basic EPS | -0.34 | -0.45 | -0.64 | -0.57 | -0.48 |
| EPS Diluted | -0.54 | -0.69 | -1.05 | -0.92 | -0.80 |
| Normalized Diluted EPS | -0.34 | -0.45 | -0.64 | -0.57 | -0.48 |
| Average Basic Shares Outstanding | 49.23M | 48.06M | 47.74M | 47.42M | 47.03M |
| Average Diluted Shares Outstanding | 49.23M | 48.06M | 47.74M | 47.42M | 47.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |